Factors such as medication interactions, adherence issues, or underlying medical conditions may require assessment and potential intervention
Importantly, no significant hepatotoxicity, nephrotoxicity, or cardiotoxicity has been observed in short- to medium-term studies (612 weeks)
More recent data has identified elevated concentrations of glutamate in several areas of the brain, which is positively correlated with pain scores
Many people find these also sit less comfortably on a GLP-1 medicine
If you notice stool colour changes whilst taking GLP-1 medication, consider recent dietary intake and any new medications or supplements before attributing the change to your GLP-1 therapy
Individual response depends on adherence, nutrition, activity, and tolerability, and is reviewed against your own data over time